Medication info
Nanubia 50 mg Tablet (Sitagliptin Hydrochloride Monohydrate)

Nanubia 50 mg Tablet (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Hankyorex Pharmaceuticals Co., Ltd.
Appearance
Light apricot-colored, round, biconvex film-coated tablet
Packaging
28 tablets/box [(14 tablets/PTP x 2)]
Approval status
Active

MFDS item code 202101256 · Approved 2021.02.10 · Insurance code 649105260

Summary

Main use
Improvement of blood glucose control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Hankyorex Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes mellitus

  • Difficulty in blood glucose control in patients with type 2 diabetes
View approved original text

This medication is used to improve blood glucose control in patients with type 2 diabetes along with dietary and exercise therapy. It can be administered as monotherapy, but if sufficient blood glucose control is difficult with monotherapy in patients with no prior experience in diabetes medication therapy, it may be combined with metformin. Additionally, if blood glucose control is challenging with monotherapy of sulfonylurea, metformin, thiazolidinediones, or insulin, this medication is used in combination. Furthermore, if blood glucose control is inadequate despite various combined treatments, this medication can be added for enhanced efficacy. This medication is used in conjunction with various treatment methods to improve blood glucose control.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy. The maximum daily dose is 100 mg. This medicine may be taken with or without food. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for use, section 5. General precautions). Patients with renal impairment Because dose adjustment based on renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or patients with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may cause severe allergic reactions, and if symptoms such as skin rash, difficulty breathing, or swelling of the face or lips occur within three months of starting treatment, it should be discontinued immediately, and a doctor should be consulted. Severe adverse effects like pancreatitis (inflammation of the pancreas) have been reported with this medication, so if symptoms such as abdominal pain, vomiting, or loss of appetite occur while taking this medication, medical advice should be sought immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and should be avoided in patients with hypersensitivity to this medication or any of its components. Patients with impaired kidney function may experience delayed excretion of this medication, thus the dosage should be reduced, and regular kidney function tests are essential. In clinical trials, patients taking this medication experienced side effects similar to colds, upper respiratory infections, headaches, abdominal pain, and diarrhea, and particularly if taken with other blood glucose-lowering agents, hypoglycemic symptoms may occur more frequently. When this medication is taken with insulin or sulfonylurea, the risk of hypoglycemia is increased, so blood glucose should be checked frequently, and the dosage of hypoglycemic agents should be adjusted as needed. If joint pain or skin blisters occur during medication use, consult a doctor immediately, and in severe cases, discontinue the medication. Pregnant or nursing women are advised against using this medication, and consultation with a doctor is mandatory before use. In the case of overdose, the drug should be removed from the gastrointestinal tract, and monitoring of the condition through an electrocardiogram may be performed, and, if necessary, dialysis may be carried out. This medication has relatively low interactions with other drugs, but it is advisable to consult healthcare providers when taking specific medications together. Elderly patients are likely to have decreased kidney function; therefore, dosage adjustment and kidney function testing are necessary when using this medication.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hypoglycemia
  • upper respiratory infection
  • nasopharyngitis
  • headache
  • diarrhea
  • abdominal pain
Show 28 more
  • nausea
  • peripheral edema
  • constipation
  • vomiting
  • severe and debilitating arthralgia
  • blistering dermatitis herpetiformis
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • elevated liver enzymes
  • acute kidney failure
  • pneumonia
  • diabetes complications
  • metabolic acidosis
  • falls
  • cardiac arrest
  • dyspepsia
  • dizziness
  • increased serum triglycerides
  • gastritis
  • weight loss
  • hypertension
  • hypernatremia
  • erectile dysfunction
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air from entering, and it is recommended to keep it at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the medication's effectiveness and prevent degradation.

Appearance and packaging

Appearance

Light apricot-colored, round, biconvex film-coated tablet

Package unit

28 tablets/box [(14 tablets/PTP x 2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.